18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia

Stölzel, Friedrich; Röllig, Christoph; Radke, Jörgen; Mohr, Brigitte; Platzbecker, Uwe; Bornhäuser, Martin; Paulus, Tobias; Ehninger, Gerhard; Zöphel, Klaus; Schaich, Markus

doi:10.3324/haematol.2011.045047

Cited by 112 publications

(110 citation statements)

References 21 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…18 FDG-PET CT imaging was recently shown by Stö lzel and colleagues to be useful in studying and following extramedullary AML [Stö lzel et al 2010].…”

Section: Pathogenesis Of Extramedullary Diseasementioning

confidence: 99%

Myeloid sarcoma: current approach and therapeutic options

Avni

Koren‐Michowitz

2011

Therapeutic Advances in Hematology

216

289

View full text Add to dashboard Cite

Myeloid sarcoma is a rare disease that can present as an isolated extramedullary leukemic tumor, concurrently with or at relapse of acute myeloid leukemia. Owing to the rarity of this disorder, most of the literature comprises small retrospective studies and case reports. The aim of this review is to summarize the current published data regarding the clinical presentation, morphological, cytogenetic and molecular features, prognosis and treatment of myeloid sarcoma.

show abstract

“…18 FDG-PET CT imaging was recently shown by Stö lzel and colleagues to be useful in studying and following extramedullary AML [Stö lzel et al 2010].…”

Section: Pathogenesis Of Extramedullary Diseasementioning

confidence: 99%

Myeloid sarcoma: current approach and therapeutic options

Avni

Koren‐Michowitz

2011

Therapeutic Advances in Hematology

216

289

View full text Add to dashboard Cite

show abstract

“…PET-CT may also be beneficial, especially for monitoring response and for radiation therapy planning. MRI may be the modality of choice when MS develops in the central nervous system (CNS) [27-32]. …”

Section: Diagnosismentioning

confidence: 99%

Myeloid Sarcoma

et al. 2019

View full text Add to dashboard Cite

Hematological malignancies can manifest as extramedullary soft tissue masses in relatively rare cases. The rarity of it causes a diagnostic and therapeutic challenge. One of the rarest manifestations is myeloid sarcoma (MS). MS develops as part of acute myeloid leukemia, myeloproliferative neoplasm, or myelodysplastic syndrome or at relapse, especially following allogeneic hematopoietic stem cell transplant. The tumor displays high myeloperoxidase expression, hence the color green, and is called chloroma. It most commonly appears in lymph nodes, skin and soft tissues, bone, testes, gastrointestinal tract, and peritoneum. Immunohistochemistry shows CD68-KP1 as the most commonly expressed marker, then myeloperoxidase, CD117, CD99, CD68/PG-M1, lysozyme, CD34, terminal deoxynucleotidyl transferase, CD56, CD61, CD30, glycophorin A, and CD4. Different chromosomal abnormalities including MLL rearrangement, t(8; 21), monosomy 7, trisomy 8, trisomy 11, trisomy 4, inversion (16), monosomy 16,16q deletion, 5q deletion, and 20q deletion were reported. Most of the literature about MS are case reports and small retrospective studies, thus there is limited clinical knowledge of the cases and their presentation and management plans. Here, we provide a review of what has been reported in the literature about MS in the light of our experiences.

show abstract

“…Myeloid sarcoma (MS) is defined as an extramedullary mass composed of myeloid blasts occurring in anatomic sites other than BM. [6] Extramedullary infiltration (EMI) is fairly common in AML patients. In addition, MS has been observed in all age groups, and may occur anywhere in the body.…”

Section: Introductionmentioning

confidence: 99%

Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia

Mohammadi-Asl¹,

Khosravi²,

Shahjahani³

et al. 2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

The myeloid extramedullary tumor is a solid tumor formed by infiltration of immature myeloid cells in various tissues of the body. This tumor is also identified as chloroma or myeloid sarcoma (MS). MS is a manifestation of acute myeloid leukemia (AML) occurring at presentation or during treatment or relapse. MS is associated with multiple chromosomal abnormalities and molecular mutations since patients with these disorders bear a high potential for MS manifestation. There is a high incidence of extramedullary infiltration (EMI) in AML. AML patients with EMI have a worse prognosis than patients without it. Hematopoietic stem cells and leukemic stem cells reside in a special bone marrow microenvironment called niche, which is essential for their normal functions. Cancers are exploited dysfunctional cell-cell and matrix-cell interactions, which convert a normal niche into a neoplastic niche. This study summarizes the current knowledge on the molecular and cellular characteristics of AML with EMI and extramedullary niches in AML patients.

show abstract

18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia

Cited by 112 publications

References 21 publications

Myeloid sarcoma: current approach and therapeutic options

Myeloid sarcoma: current approach and therapeutic options

Myeloid Sarcoma

Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia

Contact Info

Product

Resources

About